GELSHealthcare · Drug Manufacturers - Specialty & GenericGELS Stock Forecast: Gelteq Ltd. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 12 of 100 as at 22 Aug 2026 — in the weakest quartile.
GELS stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Gelteq Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (95): Smaller than most of the companies we track.
Volatility (7): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
GELS stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on GELS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GELS appears on the weeks it earns a place.
GELS analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Gelteq Ltd. (GELS) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −0.8×
- Price / sales
- 12.8×
- Price / book
- 0.6×
- EV / EBITDA
- −2.2×
Cheaper than 81% of US stocks
Cheaper than 13% of US stocks
Cheaper than 83% of US stocks
Cheaper than 72% of US stocks
- Revenue growth (YoY)
- 48.9%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- −1985.3%
- Net margin
- 0.0%
Higher than 86% of US stocks
Higher than 4% of US stocks
Higher than 30% of US stocks
- Return on equity
- −42.9%
- Return on assets
- −17.6%
- Dividend yield
- —
Higher than 23% of US stocks
Higher than 21% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
GELS vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Gelteq Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about GELS stock
How does Ticker Nerd's model rank GELS?
As at 22 Aug 2026, Gelteq Ltd. ranks 12 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (95 of 100).
What is the GELS stock forecast for 2030?
No analyst covering Gelteq Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GELS are extrapolating price history, which says nothing about the business.
How has GELS stock performed over the past year?
Gelteq Ltd. returned -56.8% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Gelteq Ltd. do?
Gelteq Ltd. is a biopharmaceutical company focused on developing and commercializing innovative gel-based formulations for various therapeutic applications.
About Gelteq Ltd.
Gelteq Ltd. is a biopharmaceutical company focused on developing and commercializing innovative gel-based formulations for various therapeutic applications. At its core, Gelteq specializes in transforming traditional oral and injectable medications into more convenient gel formats, potentially enhancing patient compliance and drug efficacy. The company operates within the healthcare and pharmaceuticals sector, targeting conditions that require precise dosing and improved delivery mechanisms. One of Gelteq’s notable features is its application of proprietary gel technology across a range of therapeutic areas, including pain management and chronic disease treatment. This technology can enhance drug absorption and provide alternative administration routes, offering potential benefits for both healthcare providers and patients. In the financial market, Gelteq Ltd. plays a role as a niche player in the biopharmaceutical industry, providing innovative solutions that could meet unmet medical needs. The company's focus on reformulating existing drugs can shorten development timelines and reduce risk compared to novel drug candidates, marking its significance in a competitive landscape where effective delivery solutions are increasingly valued.
CEO Mr. Nathan Jacob Givoni · 7 employees · Australia · https://www.gelteq.com